Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of CriPec docetaxel monotherapy in platinum-resistant ovarian cancer
2018-002117-36Phase 2Completed
- Sponsor
- Cristal Therapeutics
- Start
- Jul 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in ovarian cancer and epithelial ovarian cancer (EOC), sponsored by Cristal Therapeutics. Primary endpoint: Objective response rate. Started Jul 2018; status: completed.
02
Drugs
docetaxel
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2018-002117-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002117-36.